التفاصيل البيبلوغرافية
| العنوان: |
Study Design of a Phase 3 Randomized Controlled Trial Evaluating the Efficacy and Safety of Pegozafermin in Patients with Severe Hypertriglyceridemia. |
| المؤلفون: |
Hartsfield, Cynthia, Bhatt, Deepak, Bays, Harold, Maki, Kevin, Feng, Shibao, Agollah, Germaine, Mansbach, Hank, Kastelein, John, Parli, Teresa |
| المصدر: |
Journal of Clinical Lipidology; 2024 Supplement, Vol. 18 Issue 4, pe552-e553, 2p |
| مصطلحات موضوعية: |
FATTY liver prevention, DRUG therapy for hyperlipidemia, ANTILIPEMIC agents, PATIENT safety, STATISTICAL sampling, SEVERITY of illness index, TREATMENT effectiveness, CONFERENCES & conventions, RANDOMIZED controlled trials, DRUG efficacy, FIBROBLAST growth factors, TRIGLYCERIDES |
| مصطلحات جغرافية: |
NEVADA |
| مستخلص: |
89bio, Inc. Severe hypertriglyceridemia (SHTG; defined as greater than or equal to 500 mg/dL) increases the risk of acute pancreatitis, non-alcoholic fatty liver disease and cardiovascular disease. Currently available medications often do not reduce triglycerides to desired levels, highlighting the need for new therapeutic options. Fibroblast growth factor 21 (FGF21) is an endogenous hormone, mainly secreted by the liver, which functions as a master metabolic regulator of lipid and glucose metabolism, as well as energy expenditure. Pegozafermin (PGZ), a long acting FGF21 analog, is in development for the treatment of SHTG and non-alcoholic steatohepatitis. Previous Phase 2 data demonstrated PGZ significantly reduced TGs and hepatic steatosis and improved atherogenic lipoprotein particles and glycemic control, with a good safety and tolerability profile. These promising results led to the design of the first Phase 3 trial of PGZ for the treatment of SHTG. To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG greater than or equal to 500 to less than or equal to 2000 mg/dL) after 26 weeks of treatment. ENTRUST is a global 52-week Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of pegozafermin in patients with SHTG. Approximately 360 patients aged 22 years old or older, with baseline triglycerides between 500 and 2000 mg/dL and receiving background standard-of-care lipid-modifying therapy will be randomized in a 3:3:2 ratio to weekly subcutaneous injections of PGZ 30 mg, PGZ 20 mg, or placebo. Exclusion criteria include uncontrolled or newly diagnosed T2DM, T1DM, symptomatic gallstone/biliary disease, uncontrolled hypertension, or an acute pancreatitis event within 6 months. The primary endpoint will be percent change in fasting serum TGs from baseline after 26 weeks of PGZ/placebo treatment. Key secondary endpoints include changes in serum lipids, lipoproteins, glycemic control, liver steatosis and safety. Final efficacy analysis will be based on 52 weeks of treatment. The study was initiated in June 2023 and has an estimated primary completion date of August 2025. NCT05852431. ENTRUST is a pivotal Phase 3 clinical trial designed to confirm the efficacy and safety of PGZ in the treatment of SHTG. Expected clinical benefits include significant reductions of triglycerides and hepatic steatosis, as well as other metabolic improvements. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Lipidology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text via ClinicalKey 
Full Text Finder